Angiotensin IV analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-03. Anything still debated is marked as such rather than presented as settled.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | For lyophilized powder; avoid repeated freeze-thaw. |
| Appearance | White to off-white powder | Common for lyophilized peptides. |
| Solubility | Soluble in water and aqueous buffers | Limited solubility in nonpolar solvents. |
| Typical analytical method | Reverse-phase HPLC and mass spectrometry | Used for purity and identity checks. |
| Typical purity specification | 95% or greater by HPLC area | Supplier values vary; not a biological potency measure. |
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
The therapeutic properties of alprazolam are similar to other benzodiazepines and include anxiolytic, anticonvulsant, muscle relaxant, hypnotic, and amnesic; however, it is used mainly as an anxiolytic. Giving alprazolam, as compared to lorazepam, has been demonstrated to elicit a statistically significant increase in extracellular dopamine D1 and D2 concentrations in the striatum.
== Contraindications == Abatacept has not been tested in pregnant women and it is not known if it is secreted in breast milk; it causes birth defects in rodents when given in very high doses, and is transmitted in rodent breast milk. Abatacept will likely interfere with any vaccine given while people are taking it. It should not be used in combination with anakinra or TNF antagonists. Because abatacept, anakinra, and TNF antagonists suppress the immune system, using them in combination may significantly increase the risk for severe infections.
President Wee Kim Wee accepted her plea for clemency in 1992 and her death sentence was commuted to life imprisonment; her two accomplices, however, were executed in 1992. While serving her life sentence, she was diagnosed with cervical cancer in 1993 and had at most a year to live. She appealed to President Ong Teng Cheong for clemency so that she could be released in order to spend the final moments of her life with her family. The president accepted the petition, and she was released on 16 February 1995 and eventually died on 30 March that year. 1992: Koh Swee Beng, a Singaporean who killed a man who assaulted his foster father in 1988. He was convicted of murder and sentenced to hang in 1990. He lost his appeal against his death sentence in 1991 but was eventually granted clemency by President Wee Kim Wee on 13 May 1992 (two days before he was scheduled to be executed) and had his sentence commuted to life imprisonment. He was released from prison in September 2005 for good behaviour after serving at least two-thirds of his life sentence. 1998: Mathavakannan Kalimuthu, a Singaporean convicted of murder and sentenced to hang in 1996 along with his two friends. After losing their appeals in 1997, the three of them petitioned to President Ong Teng Cheong for clemency in 1998. The president accepted only Mathavakannan's plea so his sentence was commuted to life imprisonment; the other two had their pleas rejected and were subsequently executed. Mathavakannan was eventually released in 2012 after spending about 16 years in prison.
==== Slide preparation ==== Cells from bone marrow, blood, amniotic fluid, cord blood, tumor, and tissues (including skin, umbilical cord, chorionic villi, liver, and many other organs) can be cultured using standard cell culture techniques in order to increase their number. A mitotic inhibitor (colchicine, colcemid) is then added to the culture. This stops cell division at mitosis which allows an increased yield of mitotic cells for analysis. The cells are then centrifuged and media and mitotic inhibitor are removed, and replaced with a hypotonic solution. This causes the white blood cells or fibroblasts to swell so that the chromosomes will spread when added to a slide as well as lyses the red blood cells. After the cells have been allowed to sit in hypotonic solution, Carnoy's fixative (3:1 methanol to glacial acetic acid) is added. This kills the cells and hardens the nuclei of the remaining white blood cells. The cells are generally fixed repeatedly to remove any debris or remaining red blood cells. The cell suspension is then dropped onto specimen slides. After aging the slides in an oven or waiting a few days they are ready for banding and analysis.
=== Trypsin === While working in the laboratory of Max Bergmann at Rockefeller Institute, now Rockefeller University, Hofmann synthesized analogs of the amino acid lysine and proved that the enzyme trypsin cleaves linkages involving the carboxyl group of that amino acid.
Sources: en.wikipedia.org
Use of naloxone to treat people who have been using opioids recreationally may cause acute opioid withdrawal with distressing physiological symptoms such as shivering, tachycardia, and nausea; these in turn may lead to aggression and reluctance to receive further treatment.
6 June – BBC News reports that opposition to the Terminally Ill Adults (End of Life) Bill is growing among MPs, with a number who voted for it or abstained now saying they will vote against it. Following criticism of her performance at Prime Minister's Questions, Kemi Badenoch says she is "going to get better" as her party's leader, and is not "shy about self-criticism". Nathaniel Fried tells Politics South East that he resigned as head of Reform UK's Doge effort because the departure of Zia Yusuf left him with "a bit of doubt" about the project's future. Alexander Walker, the youngest member of Rhyl Town Council, is elected as the town's mayor at the age of 25. 7 June – Zia Yusuf announces he will return to Reform UK two days after resigning, and will run its Doge team. 8 June – The UK government says it intends to spend £86bn on the science and technology sector by the end of the current parliament. Reform's deputy leader, Richard Tice, insists the party knows "exactly what it is doing" following Zia Yusuf's departure and return. Speaking on BBC Scotland's Sunday Show, Scottish Labour leader Anas Sarwar accuses the Scottish National Party of running a "dishonest and disgraceful" campaign ahead of the Hamilton, Larkhall and Stonehouse by-election by attempting to push voters towards Reform UK, whose candidate came third in the election.
CEP-32496 (renamed RXDX-105) a small molecule inhibitor of BRAF, EGFR and RET, now in Phase I/II trials CEP-40783 (renamed RXDX-106) a small molecule inhibitor of AXL and c-Met in preclinical development CEP-40125 (renamed RXDX-107) a nanoformulation of a modified bendamustine with potential activity in solid tumours. Bendamustine Rapid Infusion as therapy for CLL and NHL is part of Teva's specialty drugs pipeline. TEV-44229 (renamed RXDX-108) a potent inhibitor of the kinase PKCiota In July 2019, the company stopped production of Vincristine, a critical drug used to treat the most common forms of childhood cancer, and was criticized by media for creating a worldwide shortage of the drug. On 28 January 2020, the company announced that the Food and Drug Administration (FDA) had approved an autoinjector device for Ajovy (fremanezumab-vfrm) injection.
=== Inherited Neurodegenerative Diseases === In 2022, a new autosomal-recessive disease was discovered that is caused by mutations of the CTR1 gene. The disease is characterized by profound deficiency of copper in the central nervous system and presents with infantile seizures and neurodegeneration. hCTR1 has been implicated in neurological disorders. Copper imbalance is a hallmark of various neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, where amyloid-β peptides bind copper and generate oxidative stress. Furthermore is's associated with Huntington’s disease, prion diseases, and Amyotrophic lateral sclerosis. The hCTR1-Atox1-ATP7A/B axis is also associated with Menkes disease and Wilson’s disease, in both cases the pathology is driven primarily by mutations in proteins that regulate copper homeostasis, most notably disease-causing mutations in ATP7A or ATP7B, which lead to systemic copper deficiency or copper overload. Moreover, the human eye, and particularly the retina, is composed of highly specialized neurons, and hCTR1 plays a vital role in maintaining copper homeostasis across ocular tissues. Increased hCTR1 expression has been reported in patients with Eales disease and copper has been identified as a major driver of vision loss in ischemic and diabetic retinopathies.
Sources: en.wikipedia.org
The lyophilized powder is commonly kept at -20 °C or lower, protected from moisture and light. Solutions may require colder storage and should avoid repeated freeze-thaw cycles. General peptide stability practices apply.
Reverse-phase HPLC can estimate purity, while mass spectrometry helps confirm molecular mass. These methods do not prove biological effects. Lot-specific certificates may provide additional data.
It is not an approved medicine in major jurisdictions. Depending on the country and marketing claims, it may be treated as a research chemical or unapproved substance. Import and sale rules vary.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.